Climb Bio, Inc.
CLYM
$7.02
-$0.11-1.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -4.49% | 41.86% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 29.57% | 39.48% | |||
| Operating Income | -29.57% | -39.48% | |||
| Income Before Tax | -35.91% | -48.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -35.91% | -48.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -35.91% | -48.72% | |||
| EBIT | -29.57% | -39.48% | |||
| EBITDA | -29.62% | -39.45% | |||
| EPS Basic | -37.20% | -47.82% | |||
| Normalized Basic EPS | -37.13% | -47.94% | |||
| EPS Diluted | -37.20% | -47.82% | |||
| Normalized Diluted EPS | -37.13% | -47.94% | |||
| Average Basic Shares Outstanding | -0.93% | 0.62% | |||
| Average Diluted Shares Outstanding | -0.93% | 0.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||